NOS2 and malaria: Careful experimental testing of certain agents that modulate monocyte activation should be considered for eventual development as adjunctive treatments for malaria in hopes of preventing/reversing the M2 monocyte/macrophage activation status, increasing NOS2 expression, decreasing IL-10, enhancing NO bioavailability, and reducing malaria severity.